MDR1 基因C3435T 多态性对重症肌无力患者环孢素血药浓度的影响

中国临床药理学与治疗学 ›› 2005, Vol. 10 ›› Issue (2): 133-136.

MDR1 基因C3435T 多态性对重症肌无力患者环孢素血药浓度的影响

张亚同, 杨莉萍¹, 邵宏, 李可欣¹, 孙春华¹, 史录文

北京大学药学院药事管理与临床药学系, 北京100083;
¹北京医院药学部, 北京100730

收稿日期:2004-12-16 修回日期:2005-02-15 出版日期:2005-02-06 发布日期:2020-11-18
通讯作者: 邵宏, 男, 博士, 副教授, 从事临床药学教学与科研工作。Tel:82801701-237 E-mail:h_shao@163.com
作者简介:张亚同, 男, 硕士, 主要从事药物遗传学和临床个体化用药研究。

Effects of MDR1 gene C3435T polymorphism on pharmacokinetics of cyclosporine A in myasthenia gravis patients

ZHANG Ya-tong, YANG Li-ping, SHAO Hong, Li Ke-xin¹, SUN Chun-hua¹, SHI Lu-wen

Department of Pharmacy Administration & Clinical Pharmacy, School of Pharmaceutical Science, Peking University, Beijing 100083, China;
¹Department of Pharmacy, Beijing Hospital, Beijing 100730, China

Received:2004-12-16 Revised:2005-02-15 Online:2005-02-06 Published:2020-11-18

摘要/Abstract

摘要： 目的:研究MDR1 基因C3435T 多态性与重症肌无力患者环孢素药物动力学的关系。方法:采用荧光PCR 的方法检测96 名重症肌无力(MG) 患者MDR1 C3435T 基因型, 其中临床资料较全的73 名,对其环孢素用药的血药检测结果与基因型结果分析。结果:重症肌无力患者MDR1 C3435T 的分布频率接近1:1;野生型3435CC 患者的环孢素全血谷浓度高于杂合型和突变型(P<0.05), 杂合型与突变型之间无明显差异。结论:药物遗传学研究对环孢素治疗重症肌无力患者的临床合理用药有指导意义。

关键词: MDR1, 重症肌无力, 环孢素, 荧光PCR, 药物遗传学

Abstract: AIM: To determine the effects of MDR1 C3435T on the pharmacokinetics of cyclosporine A in myasthenia gravis patients.METHODS: The genotype on MDR1 C3435T in 96 myasthenia gravis patients was detected using real-time PCR method and 73 patients of them were studied further to determine the relationship of MDR1 C3435T polymorphism and trough blood concentrations of cyclosporine A.RESULTS: There were no difference between normal people and myasthenia gravis patients inMDR1 C3435T distribution.The average concentrations in patient of MDR1 3435CC was higher than that in patients of MDR1 3435CT and 3435TT.CONCLUSION: The pharmacogenomics is important to rationalize the medication of cyclosporine A.

Key words: MDR1, myasthenia gravis, cyclosporine A, real-time PCR, pharmacogenomics

中图分类号:

R966

张亚同, 杨莉萍, 邵宏, 李可欣, 孙春华, 史录文. MDR1 基因C3435T 多态性对重症肌无力患者环孢素血药浓度的影响[J]. 中国临床药理学与治疗学, 2005, 10(2): 133-136.

ZHANG Ya-tong, YANG Li-ping, SHAO Hong, Li Ke-xin, SUN Chun-hua, SHI Lu-wen. Effects of MDR1 gene C3435T polymorphism on pharmacokinetics of cyclosporine A in myasthenia gravis patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(2): 133-136.

参考文献

1 Morita N, Yasumori T, Nakayama K.Human MDR1 polymorphism:G2677T/A and C3435T have no effect on MDR1 transport activities[J].Biochem Pharm, 2003;65:1843-52
2 Sakaeda T, Nakamura T, Okumura K.Pharmacogenetics of drug transporters and its impact on the pharmacotherapy[J]. Curr TopMed Chem, 2004;4:1385-98
3 Song PF, Shen L, Meibohm B, Gaber AO, Honaker MR, Kotb M, et al.Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: mdr1 single nucleotide polymorphism genotyping assay [J]. AAPS PharmSci, 2002;4:29
4 von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW.No influence of the mdr1 C3435T polymorphism or a cyp3a4 promoter polymorphism (cyp3a4-v allele) on doseadjusted cyclosporin a trough concentrations or rejection incidence in stable renal transplant recipients[J].Clin Chem, 2001;47:1048-52
5 岑宇翔, 陆志诚, 汪华侨.汉族人MDR1C3435T 基因的多态性[J].解剖学研究, 2004;26:50-3
6 梁剑宁, 李耀明, 张惠文.MDR1C3435T 基因多态性的检测[J].现代临床医学生物工程学杂志, 2003;9:72-5
7 Ameyaw MM, Regateiro F, Li T, Liu X, TariqM, Mobarek A, et al.MDR1 pharmacogenetics:frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity[J].Pharmacogenetics, 2001;11:217-21
8 Chowbaya B, Cumaraswamyb S, Cheungc YB, Zhou Q, Lee EJ.Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients[J].Pharmacogenetics, 2003;13:89-95
9 Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al.Identification of functionally variant MDR1 alleles among European Americans and African Americans[J]. Clin Pharmacol Ther, 2001;70:189-99
10 Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, et al.MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects[J].Pharm Res, 2001;18:1400-4
11 Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P, et al.Effect of grapefruit juice on digoxin pharmacokinetics in humans[J].Clin Pharmacol Ther, 2001;70:311-6
12 Min DI, Ellingrod VL.C3435T mutation in exon 26 of the human MDR1 gene and cy closporine harmacokinetics in healthy subjects[J].Ther Drug Monit, 2002;24:400-4
13 Balram C, Sharma A, Sivathasan C, Lee EJ.Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population:phenotypic-genotypic correlates[J].Br J Clin Pharmacol, 2003;56:78-83

[1]	王晖, 徐晓芳, 李荣. 治疗药物监测在环孢素A个体化给药中的应用及研究进展[J]. 中国临床药理学与治疗学, 2021, 26(6): 707-713.
[2]	杨书才，张莉，刘利平，邓唯杰，周杰，刘慧，张鲍虎，金涛. 缺氧诱导因子2α对肝细胞癌化疗耐药性的影响[J]. 中国临床药理学与治疗学, 2019, 24(6): 630-636.
[3]	郑琛，孙红，黄旭慧，魏晓霞，屈强，屈健. CYP3A5和MDR1基因多态性对沙格列汀疗效的影响[J]. 中国临床药理学与治疗学, 2016, 21(8): 921-925.
[4]	付孟龙，周宏灏. MDR1基因多态性及其临床相关性[J]. 中国临床药理学与治疗学, 2016, 21(4): 463-469.
[5]	朱宏平，靳高凤，陈亚军，李新华，张红，黄世博，夏春华，熊玉卿. 柚皮素对K562/A02细胞MDR1 mRNA/P gp的影响及机制研究[J]. 中国临床药理学与治疗学, 2016, 21(11): 1209-1214.
[6]	李力, 关业勍, 李贺, 刘炜. LC-MS/MS法同时测定人全血中四种免疫抑制剂类药物浓度[J]. 中国临床药理学与治疗学, 2015, 20(10): 1126-1130.
[7]	戴映, 张晶, 林美钦, 宋洪涛. 环孢素A的药物基因组学与个体化用药的研究现状及进展[J]. 中国临床药理学与治疗学, 2014, 19(8): 931-936.
[8]	欧阳苍鸿, 谢娟. 例心衰患者的MDR1和CYP3A基因多态性与地高辛血药浓度的相关性研究[J]. 中国临床药理学与治疗学, 2014, 19(3): 291-296.
[9]	曹迎亚, 鲁卫华, 姜小敢, 鲁美静, 吴敬医, 秦雪梅, 姚卫东. 血清乙酰胆碱受体抗体阳性和阴性重症肌无力患者罗库溴铵肌松时效的比较[J]. 中国临床药理学与治疗学, 2014, 19(10): 1153-1157.
[10]	辛华雯, 刘慧明, 李元启, 黄晖, 赵丽, 余爱荣, 李罄, 吴笑春, 李维亮, 熊磊. ABCC2基因多态性与肾移植受者环孢素所致肝功能异常的相关性研究[J]. 中国临床药理学与治疗学, 2013, 18(7): 778-784.
[11]	秦雪梅, 鲁卫华, 金孝岠, 姚卫东, 唐宁. 罗库溴胺用于重症肌无力患者胸腺切除术的肌松效应[J]. 中国临床药理学与治疗学, 2012, 17(11): 1263-1267.
[12]	孟祥光, 倪文琼, 王超, 马登轩, 李智, 周宏灏. 银屑病全身治疗的遗传药理学进展[J]. 中国临床药理学与治疗学, 2012, 17(11): 1307-1313.
[13]	朱素燕, 胡毅坚, 陈江飞, 徐萍, 龙再浩. 甘草提取物对大鼠体内环孢素药代动力学的影响[J]. 中国临床药理学与治疗学, 2011, 16(9): 971-974.
[14]	丁征, 邓婕, 宋洪涛. MDR1基因多态性对相关药物药动学影响研究进展[J]. 中国临床药理学与治疗学, 2011, 16(10): 1191-1196.
[15]	彭洪军, 季晖, 戴德哉, 戴茵. 环孢素A 改善异丙肾上腺素所致心肌损害和纤维化可能由抑制内皮素通路所介导[J]. 中国临床药理学与治疗学, 2008, 13(9): 966-971.